// App-Quantinova.ai

TPS5095 : PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.

Researchers

Presenter

  • Siamak Daneshmand

Principal Investigators

  • Petros Grivas

  • Srikala S. Sridhar

  • Shilpa Gupta

  • Joaquim Bellmunt

  • Guru Sonpavde

  • Mark T. Fleming

  • Seth P. Lerner

  • Yohann Loriot

  • Hao Wang

  • Hiywot Takkele

  • Corina Andresen

  • Jessica Rearden

  • Craig Berman

  • Sumanta K. Pal

Medical Centers

  • Keck School of Medicine of USC, Los Angeles, CA

  • University of Washington, Seattle, WA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Cleveland Clinic Foundation, Cleveland, OH

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Virginia Oncology Associates, Hampton, VA

  • Baylor College of Medicine, Houston, TX

  • Institut Gustave Roussy, Nantes, France

  • Halozyme Therapeutics, Inc., San Francisco, CA

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Fibroblast growth factor receptor 3

  • Ribosomal Protein S27a

  • Plasma cell-free DNA

Drug/Treatment

  • Infigratinib

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • NCT04197986

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved